UNSPSC 51111858: Liarozole

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C17H13ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0Q29TGV9Y, chemically known as 1h-benzimidazole, 5-((3-chlorophenyl)-1h-imidazol-1-ylmethyl)- but generally known as liarozole, which bears US NIH Compound Identifier 60652. European Medicines Agency schedules Liarozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14356MIG.

UNSPSC 51111858 Liarozole, a Commodity code, covers generic pharmaceutical products that state and local governments procure through cooperative purchasing vehicles and direct supply agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicits manufacturers of generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities. The scope includes pharmaceuticals with specific National Drug Codes (NDC), requiring vendors to supply detailed product information, comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and offer flexible pricing structures including flat price, net price formats (NF30, NF60, NF90), or WAC-minus options. Vendors must carry comprehensive insurance including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. Cooperative purchasing alliances like MMCAP are the primary issuing mechanism for this code, pooling demand across multiple jurisdictions to achieve scale.

MMCAP's procurement spans Minnesota and subordinate participating states including Oregon. The alliance issued an RFP (S1070000015802) on January 20, 2026, with a March 26, 2026 proposal deadline and a February 18, 2026 cutoff for questions. Awards are expected to become effective July 1, 2026, with products required to be available in the marketplace by May 15, 2026. Contract terms extend two years for new responders with optional extensions at MMCAP's discretion, while incumbent amendments align with existing expiration dates through June 30, 2028. Evaluation weighting emphasizes price competitiveness at 75 percent, with smaller weights on fixed pricing (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). MMCAP reserves authority for sole, dual, or multi-awards based on therapeutic considerations and member-specific needs. Specific contract values or budget ranges are not disclosed; however, vendors should anticipate performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.